Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease

There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and G...

Descripción completa

Detalles Bibliográficos
Autores principales: Abrams, Rory M.C., Kim, Brian D., Markantone, Desiree M., Reilly, Kaitlin, Paniz-Mondolfi, Alberto E., Gitman, Melissa R., Choo, S. Yoon, Tse, Winona, Robinson-Papp, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384559/
https://www.ncbi.nlm.nih.gov/pubmed/32720233
http://dx.doi.org/10.1007/s13365-020-00884-7
Descripción
Sumario:There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.

Ejemplares similares